$1.11
+0.02 (+1.83%)
Open$1.10
Previous Close$1.09
Day High$1.29
Day Low$1.09
52W High$8.35
52W Low$4.52
Volume—
Avg Volume381.8K
Market Cap28.36M
P/E Ratio53.43
EPS$0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+570.3% upside
Current
$1.11
$1.11
Target
$7.44
$7.44
$4.65
$7.44 avg
$8.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.30M | 4.98M | 4.38M |
| Net Income | -11,481 | -9,902 | -8,948 |
| Profit Margin | -0.2% | -0.2% | -0.2% |
| EBITDA | -10,930 | -11,209 | -8,630 |
| Free Cash Flow | -9,428 | -11,072 | -6,340 |
| Rev Growth | +3.9% | +11.7% | +7.6% |
| Debt/Equity | 0.42 | 0.41 | 0.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |